Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:FOLDNASDAQ:GERNNASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$29.29+0.2%$30.15$22.90▼$36.45$4.83B0.441.74 million shs804,017 shsFOLDAmicus Therapeutics$6.24+3.1%$6.15$5.51▼$12.65$1.92B0.513.18 million shs2.28 million shsGERNGeron$1.38+0.4%$1.44$1.17▼$5.06$875.76M0.6411.25 million shs6.23 million shsLGNDLigand Pharmaceuticals$114.63+0.8%$108.51$85.18▼$129.90$2.21B0.84117,885 shs66,703 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+1.67%+2.17%-7.82%+3.69%+20.34%FOLDAmicus Therapeutics-1.71%+5.58%-1.79%-9.97%-39.62%GERNGeron-3.86%-2.84%-14.38%+7.03%-69.76%LGNDLigand Pharmaceuticals-0.55%+0.07%+7.33%+17.68%+34.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.927 of 5 stars4.43.00.04.23.42.51.9FOLDAmicus Therapeutics3.6807 of 5 stars3.41.00.04.30.60.01.9GERNGeron2.8658 of 5 stars3.41.00.01.30.61.70.6LGNDLigand Pharmaceuticals4.8006 of 5 stars3.53.00.04.42.63.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.83Moderate Buy$40.0036.57% UpsideFOLDAmicus Therapeutics 2.70Moderate Buy$16.22159.97% UpsideGERNGeron 2.78Moderate Buy$5.06268.18% UpsideLGNDLigand Pharmaceuticals 3.00Buy$146.1427.49% UpsideCurrent Analyst Ratings BreakdownLatest GERN, ALKS, LGND, and FOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$33.00 ➝ $42.005/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/8/2025GERNGeronScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.505/2/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/2/2025ALKSAlkermesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$39.00 ➝ $40.005/2/2025ALKSAlkermesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$38.00 ➝ $41.005/2/2025FOLDAmicus TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.005/2/2025FOLDAmicus TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.004/28/2025ALKSAlkermesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderperform ➝ Underperform(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.51B3.19$2.69 per share10.88$9.05 per share3.24FOLDAmicus Therapeutics$543.14M3.54N/AN/A$0.65 per share9.60GERNGeron$116.29M7.53N/AN/A$0.46 per share2.99LGNDLigand Pharmaceuticals$181.49M12.19$1.61 per share71.31$43.95 per share2.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0914.0121.381.7923.30%27.52%17.98%7/23/2025 (Estimated)FOLDAmicus Therapeutics-$56.11M-$0.09N/A14.51N/A-5.41%4.67%1.05%8/14/2025 (Estimated)GERNGeron-$174.57M-$0.21N/AN/AN/A-119.54%-47.86%-26.78%8/6/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$7.12N/A30.90N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)Latest GERN, ALKS, LGND, and FOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025LGNDLigand Pharmaceuticals$1.54N/AN/AN/A$43.87 millionN/A7/23/2025Q2 2025ALKSAlkermes$0.42N/AN/AN/A$343.20 millionN/A5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/7/2025Q1 2025GERNGeron-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 million5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.332.92FOLDAmicus Therapeutics2.023.342.47GERNGeron0.447.876.97LGNDLigand PharmaceuticalsN/A5.275.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%FOLDAmicus TherapeuticsN/AGERNGeron73.71%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%FOLDAmicus Therapeutics2.20%GERNGeron7.42%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800164.90 million157.65 millionOptionableFOLDAmicus Therapeutics480307.93 million301.16 millionOptionableGERNGeron70636.92 million589.66 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.94 millionOptionableGERN, ALKS, LGND, and FOLD HeadlinesRecent News About These CompaniesBrokerages Set Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PT at $146.14July 8 at 2:39 AM | americanbankingnews.comCalamos Advisors LLC Has $2.10 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 6 at 5:34 AM | marketbeat.comLigand Pharmaceuticals Incorporated (LGND) - Yahoo FinanceJuly 5 at 7:18 AM | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Buy" from AnalystsJuly 5 at 2:21 AM | marketbeat.comAllspring Global Investments Holdings LLC Has $10.14 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 4, 2025 | marketbeat.comLigand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In JulyJuly 2, 2025 | finanznachrichten.dePelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand PharmaceuticalsJuly 2, 2025 | quiverquant.comQLigand Announces Completion of Pelthos Therapeutics Merger with Channel TherapeuticsJuly 2, 2025 | globenewswire.comPelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private PlacementJuly 2, 2025 | globenewswire.comLisanti Capital Growth LLC Acquires 13,565 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 29, 2025 | marketbeat.comLGND Ligand Pharmaceuticals Incorporated - Seeking AlphaJune 26, 2025 | seekingalpha.comAndrew Reardon Sells 500 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockJune 26, 2025 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,040.00 in StockJune 25, 2025 | marketbeat.comLigand Pharmaceuticals: Attractive Royalty Model Powers ForwardJune 24, 2025 | seekingalpha.comAdvisor Resource Council Makes New $2.24 Million Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 21, 2025 | marketbeat.comSG Americas Securities LLC Acquires 5,201 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 21, 2025 | marketbeat.comChicago Capital LLC Has $58.30 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 17, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Takes $286,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 16, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,270.00 in StockJune 13, 2025 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 500 SharesJune 12, 2025 | marketbeat.comLGND Makes Bullish Cross Above Critical Moving AverageJune 11, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeChina Market Movers: MCHI, PDD, BIDU Show Bullish TrendsBy Gabriel Osorio-Mazilli | June 16, 2025View China Market Movers: MCHI, PDD, BIDU Show Bullish TrendsTariff Talks Advance, What Taiwan Semiconductor Can DeliverBy Gabriel Osorio-Mazilli | June 16, 2025View Tariff Talks Advance, What Taiwan Semiconductor Can DeliverGERN, ALKS, LGND, and FOLD Company DescriptionsAlkermes NASDAQ:ALKS$29.29 +0.06 (+0.21%) As of 03:09 PM EasternAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Amicus Therapeutics NASDAQ:FOLD$6.24 +0.19 (+3.14%) As of 03:10 PM EasternAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Geron NASDAQ:GERN$1.38 +0.01 (+0.36%) As of 03:09 PM EasternGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Ligand Pharmaceuticals NASDAQ:LGND$114.63 +0.87 (+0.76%) As of 03:10 PM EasternLigand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
